The value of cell‐free DNA for molecular pathology
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Over the past decade, advances in molecular biology and genomics techniques have revolutionized the diagnosis and treatment of cancer. The technological advances in tissue profiling have also been applied to the study of cell‐free nucleic acids, an area of increasing interest for molecular pathology. Cell‐free nucleic acids are released from tumour cells into the surrounding body fluids and can be assayed non‐invasively. The repertoire of genomic alterations in circulating tumour DNA (ctDNA) is reflective of both primary tumours and distant metastatic sites, and ctDNA can be sampled multiple times, thereby overcoming the limitations of the analysis of single biopsies. Furthermore, ctDNA can be sampled regularly to monitor response to treatment, to define the evolution of the tumour genome, and to assess the acquisition of resistance and minimal residual disease. Recently, clinical ctDNA assays have been approved for guidance of therapy, which is an exciting first step in translating cell‐free nucleic acid research tests into clinical use for oncology. In this review, we discuss the advantages of cell‐free nucleic acids as analytes in different body fluids, including blood plasma, urine, and cerebrospinal fluid, and their clinical applications in solid tumours and haematological malignancies. We will also discuss practical considerations for clinical deployment, such as preanalytical factors and regulatory requirements. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationDetection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“Ranging from small [1] or large [2] gene panels to whole exome sequencing (WES) [3], NGS analysis leads not only to new insights into the genomic landscape of cancer [4–7], but also to the identification of clinically actionable genetic alterations and biomarkers that predict treatment outcomes for specific therapies;…”
BackgroundSelf-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · cited 1×
“In this regard, cell-free DNA (cfDNA) has created new possibilities for non-invasive diagnosis and therapy monitoring [16,17].”
BackgroundSelf-citationDetection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220 · cited 1×
“Conversely, low ctDNA levels or an absence of ctDNA have been shown to correlate with treatment response [20,22,24,41,52,53], a change that can be observed earlier than with other clinical detection methods [20,24,54,55].”
ResultAnalysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207 · cited 2×
“ctDNA can contain mutations missed in biopsy studies because of tumour heterogeneity or lesions in distant sites, and is generally found in larger quantities in the bloodstream than circulating tumour cells [20].”
BackgroundResultSelf-citationAACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624 · cited 1×
“Smaller panels can be sequenced deeply to detect mutations with a mutant allele fraction (MAF) of ∼1% [73,75,76], whereas larger panels are generally sequenced to a lower depth, and therefore require a MAF of >5% for de novo mutation detection [77].”
BackgroundSelf-citationTie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492 · cited 1×
“A similar study, performed on patients with early-stage CRC, found that the absence of ctDNA after resection was predictive of recurrence-free survival at 3 years, whereas those with ctDNA detection after serial sampling had 100% recurrence [99].”
Origins, structures, and functions of circulating DNA in oncology
Thierry, A. R., El Messaoudi, S., Gahan, P. B., Anker, P., & Stroun, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9629-x · Cited by 818 · cited 3×
“ctDNA fragments are slightly shorter, with the majority being <167 bp [19,26,27,31].”
BackgroundOxnard, G. R., Paweletz, C. P., Kuang, Y., Mach, S. L., O'Connell, A., Messineo, M. M., Luke, J. J., Butaney, M., Kirschmeier, P., Jackman, D. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2482 · Cited by 786 · cited 1×
“Serial sampling can be performed to identify resistant clones prior to the onset of clinical progression [88,89].”
BackgroundLanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695
Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., Shill, H., Adler, C., Sabbagh, M., Villa, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094839 · Cited by 385
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde, I., Bettegowda, C., Wang, Y., Wu, J., Agrawal, N., Shih, I.-M., Kurman, R., Dao, F., Levine, D. A., Giuntoli, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004952 · Cited by 327 · cited 1×
“A recent study identified tumour-derived mutations in DNA extracted from Pap smears in 100% of endometrial cancer patients and 41% of ovarian cancer patients [173], offering the potential for early screening.”
BackgroundMarchetti, A., Palma, J. F., Felicioni, L., De Pas, T. M., Chiari, R., Del Grammastro, M., Filice, G., Ludovini, V., Brandes, A., Chella, A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000643 · Cited by 182
Terrin, L., Rampazzo, E., Pucciarelli, S., Agostini, M., Bertorelle, R., Esposito, G., DelBianco, P., Nitti, D., & De Rossi, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0478 · Cited by 91
Cited by
The emerging role of cell-free DNA as a molecular marker for cancer management
Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2019.100087 · Cited by 566
van der Pol, Y., & Mouliere, F. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.003 · Cited by 324
Self-citationctDNA as a cancer biomarker: A broad overview
Pessoa, L. S., Heringer, M., & Ferrer, V. P. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103109 · Cited by 298
Unlocking the Potential of ctDNA in Sarcomas: A Review of Recent Advances
Aiyer, S., Kim, T.-H., Collier, K., Pollock, R., Verschraegen, C., Stover, D. G., & Tinoco, G. (2025) · Cancers · doi:10.3390/cancers17061040 · Cited by 11
“A smaller fraction of cfDNA, known as ctDNA, is derived from tumors in patients with cancer [27–29]. of normal DNA from leukocytes and other normal cells; thus, it can be detected in patients without malignancy [22–26].”
Mangum, R., Reuther, J., Sen Baksi, K., Gandhi, I., Zabriskie, R. C., Recinos, A., Raesz-Martinez, R., Lin, F. Y., Potter, S. L., Sher, A. C., et al. (2023) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2023.2228837 · Cited by 8
Metadata
- Authors
- Stewart, C. M., Kothari, P. D., Mouliere, F., Mair, R., Somnay, S., Benayed, R., Zehir, A., Weigelt, B., Dawson, S., Arcila, M. E., Berger, M. F., & Tsui, D. W.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2018-03-12
- Volume
- 244
- Issue
- 5
- Pages
- 616-627
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2792617097
- Cited by
- 125
- References
- 20
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.